Jan 31, 2023 / NTS GMT
Alfred Chan - Emerald Financial - Analyst
Good morning, everyone. The clock has just ticked past 11:30. So we'll get started with today's quarterly investor briefing with Pharmaxis' CEO, Gary Phillips, who is going to provide an update on the clinical trial program. My name is Alfred, and I'm from Pharmaxis's Investor Relations team. And I'll just be online to assist with running the briefing. Just quick run through the formalities. After the presentation, Gary will be taking questions from attendees.
(Event Instructions)
Obviously, last day of a quarterly. So it's very busy day on the ASX, but Gary has been very generous with his time to offer this update and take any questions.
So Gary, I won't take up anymore of your time. Let me hand over to you.
Gary Phillips - Pharmaxis Limited - CEO
Okay. Thanks, Alfred. And thank you, I see we've got quite a few people online. So thank you for the interest that you continue to show in Pharmaxis. We have a busy few months ahead of us, so I think this update aims to both review some of the
Pharmaxis Investor Briefing Recording Transcript
Jan 31, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers